Giant Biogene Holding Co., Ltd. (2367.HK): BCG Matrix [Apr-2026 Updated]

Giant Biogene's portfolio is clearly weighted toward high-margin collagen skincare stars-led by Kefumei and a booming DTC channel-that fuel growth and justify heavy marketing and capex, while stable cash cows like medical dressings and Collgene underpin R&D and liquidity; the company must now decide how aggressively to fund high-potential but capital-intensive question marks (injectable fillers, international expansion, new anti‑aging lines) even as it phases out low-return dogs (ginsenoside supplements, legacy functional foods and private‑label contracts), making its allocation choices the decisive factor for sustaining momentum.

Giant Biogene Holding Co., Ltd. (2367.HK) - BCG Matrix Analysis: Stars

The Kefumei brand functions as the primary 'Star' within Giant Biogene's portfolio, contributing 81.7% of total group revenue in H1 2025 and delivering sustained high growth and margins.

Kefumei performance highlights:

• Revenue contribution: 81.7% of group revenue (H1 2025)
• Year-on-year revenue growth: 22.7% (H1 2025)
• Gross margin at brand level: 81.7%
• Key SKUs driving growth: Collagen Stick, Focus Cream
• Repeat purchase rate: materially above medical-grade skincare industry average (company disclosure)

The brand's market leadership in recombinant collagen functional skincare is reinforced by platform investments and consumer mindshare, with direct-to-consumer (DTC) channels representing 58.4% of Kefumei revenue through Tmall, Douyin and proprietary channels.

The online direct sales channel is itself a Star, delivering the bulk of near-term growth and cash generation as the company scales omnichannel operations.

Online channel metrics (Interim 2025):

• Online DTC share of company revenue: 74.7%
• Online DTC revenue: RMB 2.325 billion (H1 2025)
• Online DTC YoY growth: 26.5%
• JD.com direct-to-platform growth: +134% YoY
• Selling expense ratio (marketing intensity): ~34%
• Role: immediate cash flow, high visibility for new product rollouts

The recombinant collagen functional skincare product line is a high-growth Star within the portfolio, having become the largest category and outpacing legacy medical dressing sales.

Functional skincare segment data (mid-2025):

• Segment revenue: RMB 2.41 billion
• YoY growth: 24.2%
• Gross profit margin: >82%
• Number of ongoing R&D projects (synthetic biology platform): 140
• New channel expansions: entry into Sephora China and premium retail
• Second-tier product traction: Collagen Toner, Hydration Series accelerating faster than company average

Key strategic implications for the Star cluster within Giant Biogene:

• Maintain elevated marketing spend (selling expense ratio ~34%) to defend and extend online customer acquisition and brand mindshare.
• Prioritize capital expenditures toward DTC infrastructure and omnichannel logistics to support 58.4% DTC revenue contribution and further scale JD/Tmall/Douyin performance.
• Leverage >82% gross margins in functional skincare to fund R&D (140 projects) and premium channel entry while sustaining high ROI on hero SKUs.
• Monitor competitive intensity in recombinant collagen and premium retail channels; use targeted promotions and loyalty programs to protect repeat purchase rates.

Giant Biogene Holding Co., Ltd. (2367.HK) - BCG Matrix Analysis: Cash Cows

Cash Cows

Professional medical dressings provide stable liquidity.

Recombinant collagen medical dressings remain a foundational cash cow, generating RMB 693 million in revenue as of June 2025 with a steady year-on-year growth rate of 17.1%. This mature segment delivers high gross and operating margins relative to the group average, supports ongoing R&D investment, and sustains corporate cash flow while requiring limited incremental capital expenditure due to entrenched hospital and pharmacy distribution networks. The company has been the largest collagen-based professional skin treatment provider in China for more than five consecutive years, and the segment's predictable revenue profile underpins funding for higher-risk pipeline activities (notably medical aesthetic injectables).

Collgene brand maintains high premium margins.

The Collgene consumer skincare line serves as a strong margin contributor and operates as a quasi-cash cow within the portfolio. In 1H2025 Collgene recorded RMB 503 million in revenue (16.1% of group revenue) with 26.9% growth year-on-year. The brand's upgraded hero products (e.g., Big Mask 3.0) rank highly on major e-commerce platforms and sustain a net profit margin of approximately 32%. Capital intensity for Collgene is moderate and concentrated on product iteration, marketing and channel management rather than heavy capex. High cash conversion from Collgene helps the group maintain a net gearing ratio of -56.5%, reflecting a net cash position and strong liquidity buffer.

Offline distributor network ensures market reach.

The traditional offline distributor channel continues to generate reliable cash flow, accounting for roughly 25.3% of total group sales in 2025. Growth in this channel is measured at about 12.1% year-on-year, but its strategic value lies in institutional penetration: access to over 1,000 hospitals and thousands of pharmacy outlets creates a durable competitive moat with low churn and high ROI. Because the channel leverages long-standing partnerships, ongoing marketing and onboarding investment needs are lower versus digital channels; profits are recurrently reallocated to the group's transition toward higher-growth medical aesthetic devices.

Cash deployment and reinvestment priorities

• R&D funding for medical aesthetic injectable pipeline - financed primarily by cash from medical-grade products and Collgene.
• Targeted product iteration and marketing spend for Collgene to preserve premium positioning with moderate capital outlay.
• Maintenance of offline distributor relationships and minimal channel reinvestment to sustain institutional sales and high ROI.
• Selective M&A or strategic partnerships in medical aesthetic devices funded from operating cash surplus and net cash balance.

Giant Biogene Holding Co., Ltd. (2367.HK) - BCG Matrix Analysis: Question Marks

Dogs - Question Marks

Giant Biogene's position across several emerging high-growth but low-share initiatives places these businesses squarely in the 'Question Marks' quadrant of the BCG matrix. These initiatives require strategic capital allocation, commercial capability building and regulatory navigation to either scale toward 'Stars' or be divested. Key question marks include medical aesthetic injectable fillers, international market expansion, and new anti‑aging product series.

Medical aesthetic injectable fillers target growth: the company received approval for a Class III medical device in October 2025 - a recombinant Type I natural sequence collagen facial injectable (first of its kind in China). This product targets dynamic wrinkle correction in a high-growth aesthetic market projected to expand at >8% CAGR regionally over 2026-2031. Despite being an early mover, Giant Biogene's current share of the total injectable filler market is negligible (<1%), with incumbents such as Imeik controlling an estimated 40-60% combined share in China.

International market expansion seeks global share: international revenue remains a small fraction of total revenue (<10% currently). Giant Biogene's international push focuses on Southeast Asia and selected markets, leveraging 186 authorized and pending patents in synthetic biology. The global recombinant collagen market is forecast to grow at a double‑digit CAGR through 2031 (consensus: ~12-15% CAGR). High regulatory and market entry costs (localized trials, registration, distribution) result in low short‑term ROI; success requires scale and local regulatory/commercial investment to compete with global leaders such as Merck and Avantor.

• Patents supporting expansion: 186 authorized/pending in synthetic biology
• International revenue share: <10% of total
• Global recombinant collagen CAGR: ~12-15% through 2031 (industry estimates)
• Projected regulatory and market entry cost per country: USD 1-5 million (varies by jurisdiction)

New anti‑aging series face market uncertainty: the Precise and Intensive Repair Series and other anti‑aging launches are question marks due to underwhelming initial sales relative to the company's historical 'star' products (e.g., original Collagen Stick). Marketing investment has been ramped up to rebuild brand momentum after prior controversies; R&D expenses are modest today (1.3% of revenue) but are projected to rise as commercialization and reformulation efforts continue. Profitability hinges on achieving scale and repeat purchase rates similar to blockbuster legacy SKUs.

Critical strategic requirements across these question marks include:

• Allocate targeted capex for commercialization: sales team recruitment, clinic onboarding, distributor agreements (estimated incremental annual spend: RMB 50-150 million during scale‑up).
• Prioritize regulatory roadmaps and localized clinical data to shorten time‑to‑market in target foreign jurisdictions (per‑market regulatory spend USD 1-5 million).
• Increase R&D investment above the current 1.3% of revenue to support formulation, clinical trials and lifecycle extensions (recommended target 2.5-4.0% during heavy development phase).
• Monitor unit economics in aesthetic injectables and anti‑aging series to determine go/no‑go thresholds (target gross margin >60% for injectables at scale; payback <36 months for sales force investment).

Giant Biogene Holding Co., Ltd. (2367.HK) - BCG Matrix Analysis: Dogs

Dogs

Legacy ginsenoside health supplements show stagnation

The rare ginsenoside-based functional food and supplement segment has become a low-growth dog, contributing less than 3.0% of total corporate revenue in 2025. This legacy unit recorded year-over-year revenue growth of -0.5% in 2025 versus the company-wide collagen portfolio expansion of 22.5%. Market share in the fragmented Chinese nutraceutical market is estimated at under 0.8% for these SKUs. Operating margin for the ginsenoside line is approximately 11-14%, materially below the group's average gross margin of 81.7% and well under corporate blended operating margins. Rising raw material and extraction costs have compressed margins by an estimated 600-850 basis points since 2022. Capital allocation has been effectively minimized with near-zero incremental capex authorized for 2025; working capital has been limited to routine inventory maintenance only.

Non-core traditional functional food products decline

Traditional functional food SKUs that do not leverage Giant Biogene's proprietary recombinant collagen technology are being deprioritized. Revenue from this sub-segment was essentially flat in 2025 (growth range -1.0% to 0.0%), while the company's skincare and collagen-led products delivered double-digit growth. Return on assets (ROA) for the traditional sub-segment is low (estimated 2.0-3.5%), and contribution margin is below corporate targets. R&D investment into non-collagen traditional lines has been reallocated to the firm's 140 ongoing collagen-related projects; R&D hours and budget have decreased by an estimated 45% for non-core products since 2023. Given low strategic alignment with the 'scientific aesthetics' brand and limited upside, these products are candidates for divestment or discontinuation.

• 2025 revenue growth (traditional non-collagen): -1.0% to 0.0%
• Estimated ROA: 2.0-3.5%
• R&D reallocation: ~45% reduction in non-core R&D spend since 2023
• Strategic value: Low

Legacy private label manufacturing contracts expire

Small-scale private label manufacturing for third-party brands has declined to a negligible portion of the business, representing approximately 0.4-0.6% of 2025 revenue. These contracts historically delivered low single-digit margins and did not utilize the company's high-value brand equity or direct-to-consumer channels. The company reports zero capital expenditure allocated to maintain these legacy production lines in the 2025 fiscal year. Existing contracts are allowed to expire; capacity is being reallocated to high-demand Kefumei and Collgene product lines where margins and throughput are superior. The private label sub-segment's market share is effectively non‑existent in the premium segment, and projected EBITDA contribution over the next 24 months is immaterial.

• Share of 2025 revenue (private label): 0.4-0.6%
• Capex 2025 to legacy lines: HKD 0 (cut to zero)
• Margin profile: Low single digits
• Capacity reallocation: Toward Kefumei & Collgene high-margin lines